GlassScriptPhysician profile
James Randall Hansbrough
NPI 1255335006
$12,322.87
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,985 · 2020: $1,888 · 2021: $2,778 · 2022: $4,691 · 2023: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.83 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $2,250.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,631.44 | 2019-2023 | Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,444.93 | 2019-2023 | Ofev |
| Glaxosmithkline, LLC. | $1,392.03 | 2019-2023 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $643.45 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $516.58 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $405.80 | 2019-2023 | Dupixent |
| Insmed, INC. | $337.12 | 2020-2023 | Arikayce |
| Jazz Pharmaceuticals INC. | $336.05 | 2019-2023 | |
| Genentech USA, INC. | $325.10 | 2019-2023 | Xolair |
| Mylan Specialty L.P. | $307.25 | 2019-2022 | |
| Electromed, INC. | $272.99 | 2021-2023 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $244.00 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $228.53 | 2021-2023 | Acthar |
| Grifols USA, LLC | $222.27 | 2019-2023 | Prolastin-C Liquid |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hansbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.